Crossmark

Construction of a predictive model for immunotherapy efficacy in lung squamous cell carcinoma based on the degree of tumor-infiltrating immune cells and molecular typing

Crossref DOI link: https://doi.org/10.1186/s12967-022-03565-7

Published Online: 2022-08-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Yang, Lingge

Wei, Shuli

Zhang, Jingnan

Hu, Qiongjie

Hu, Wansong

Cao, Mengqing

Zhang, Long

Wang, Yongfang

Wang, Pingli

Wang, Kai http://orcid.org/0000-0003-4328-8799
Funding

Funding for this research was provided by:

National Natural Science Foundation of China (81902331, 81871874)

Provincial key research and development project (2020C03027, WKJ-ZJ-2122)
License Information

Text and Data Mining valid from 2022-08-12

Version of Record valid from 2022-08-12
More Information

Article History

Received: 2 May 2022

Accepted: 2 August 2022

First Online: 12 August 2022

Declarations

:

: The studies involving human participants were reviewed and approved by the Medical Ethics Committee of the Second Affiliated Hospital of Zhejiang University School of Medicine (Approval Number: 2022-0548/I2022685). The patients/participants provided their written informed consent to participate in this study.

: Not applicable.

: The authors declare that they have no competing interests.

Document is current

Any future updates will be listed below